The Neurology of mTOR

Neuron

Volumn 84, Issue 2, 2014, Pages 275-291

  Lipton, Jonathan O ^a,b   Sahin, Mustafa ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; EVEROLIMUS; FRAGILE X MENTAL RETARDATION PROTEIN; GLUTAMIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C; VASCULOTROPIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AGING; ALZHEIMER DISEASE; AUTISM; AUTOPHAGY; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME SYNTHESIS; EPILEPSY; FRAGILE X SYNDROME; GENE EXPRESSION; GUIDANCE MOLECULE; HAMARTOMA; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MEMORY; MOLECULE; NERVE CELL PLASTICITY; NEURAL STEM CELL; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA TRANSLATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUBEROUS SCLEROSIS; ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NEURONAL PLASTICITY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84908232014     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.09.034     Document Type: Review

References (216)

1. Abs E., Goorden S.M., Schreiber J., Overwater I.E., Hoogeveen-Westerveld M., Bruinsma C.F., Aganović E., Borgesius N.Z., Nellist M., Elgersma Y. TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice. Ann. Neurol. 2013, 74:569-579.
2. Alfaiz A.A., Micale L., Mandriani B., Augello B., Pellico M.T., Chrast J., Xenarios I., Zelante L., Merla G., Reymond A. TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease. Hum. Mutat. 2014, 35:447-451.
3. Allen A.S., Berkovic S.F., Cossette P., Delanty N., Dlugos D., Eichler E.E., Epstein M.P., Glauser T., Goldstein D.B., Han Y., et al. De novo mutations in epileptic encephalopathies. Nature 2013, 501:217-221. Epi4K Consortium, Epilepsy Phenome/Genome ProjectEpilepsy Phenome/Genome Project.
4. An W.-L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.-G., Winblad B., Pei J.-J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 2003, 163:591-607.
5. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997, 12:25-31.
6. Antion M.D., Merhav M., Hoeffer C.A., Reis G., Kozma S.C., Thomas G., Schuman E.M., Rosenblum K., Klann E. Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. Learn. Mem. 2008, 15:29-38.
7. Asato M.R., Hardan A.Y. Neuropsychiatric problems in tuberous sclerosis complex. J.Child Neurol. 2004, 19:241-249.
8. Auerbach B.D., Osterweil E.K., Bear M.F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011, 480:63-68.
9. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
10. Banerjee S., Crouse N.R., Emnett R.J., Gianino S.M., Gutmann D.H. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc. Natl. Acad. Sci. USA 2011, 108:15996-16001.
11. Banko J.L., Poulin F., Hou L., DeMaria C.T., Sonenberg N., Klann E. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J.Neurosci. 2005, 25:9581-9590.
12. Banko J.L., Hou L., Poulin F., Sonenberg N., Klann E. Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 2006, 26:2167-2173.
13. Banko J.L., Merhav M., Stern E., Sonenberg N., Rosenblum K., Klann E. Behavioral alterations in mice lacking the translation repressor 4E-BP2. Neurobiol. Learn. Mem. 2007, 87:248-256.
14. Bar-Peled L., Schweitzer L.D., Zoncu R., Sabatini D.M. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 2012, 150:1196-1208.
15. Bar-Peled L., Chantranupong L., Cherniack A.D., Chen W.W., Ottina K.A., Grabiner B.C., Spear E.D., Carter S.L., Meyerson M., Sabatini D.M. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013, 340:1100-1106.
16. Barbero-Camps E., Fernández A., Martínez L., Fernández-Checa J.C., Colell A. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease. Hum. Mol. Genet. 2013, 22:3460-3476.
17. Bateup H.S., Johnson C.A., Denefrio C.L., Saulnier J.L., Kornacker K., Sabatini B.L. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 2013, 78:510-522.
18. Baybis M., Yu J., Lee A., Golden J.A., Weiner H., McKhann G., Aronica E., Crino P.B. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann. Neurol. 2004, 56:478-487.
19. Beaumont V., Zhong N., Fletcher R., Froemke R.C., Zucker R.S. Phosphorylation and local presynaptic protein synthesis in calcium- and calcineurin-dependent induction of crayfish long-term facilitation. Neuron 2001, 32:489-501.
20. Bercury K.K., Dai J., Sachs H.H., Ahrendsen J.T., Wood T.L., Macklin W.B. Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination. J.Neurosci. 2014, 34:4466-4480.
21. Berdichevsky Y., Dryer A.M., Saponjian Y., Mahoney M.M., Pimentel C.A., Lucini C.A., Usenovic M., Staley K.J. PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. J.Neurosci. 2013, 33:9056-9067.
22. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
23. Bhattacharya A., Kaphzan H., Alvarez-Dieppa A.C., Murphy J.P., Pierre P., Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76:325-337.
24. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N.Engl. J. Med. 2008, 358:140-151.
25. Boer K., Troost D., Jansen F., Nellist M., van den Ouweland A.M., Geurts J.J., Spliet W.G., Crino P., Aronica E. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. Neuropathology 2008, 28:577-590.
26. Bové J., Martínez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 2011, 12:437-452.
27. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
28. Bruni O., Cortesi F., Giannotti F., Curatolo P. Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain Dev. 1995, 17:52-56.
29. Buckmaster P.S., Lew F.H. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J.Neurosci. 2011, 31:2337-2347.
30. Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J.Med. Genet. 2005, 42:318-321.
31. Caccamo A., Maldonado M.A., Majumder S., Medina D.X., Holbein W., Magrí A., Oddo S. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J.Biol. Chem. 2011, 286:8924-8932.
32. Cao R., Li A., Cho H.Y., Lee B., Obrietan K. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J.Neurosci. 2010, 30:6302-6314.
33. Cao R., Robinson B., Xu H., Gkogkas C., Khoutorsky A., Alain T., Yanagiya A., Nevarko T., Liu A.C., Amir S., Sonenberg N. Translational control of entrainment and synchrony of the suprachiasmatic circadian clock by mTOR/4E-BP1 signaling. Neuron 2013, 79:712-724.
34. Capo-Chichi J.-M., Tcherkezian J., Hamdan F.F., Décarie J.C., Dobrzeniecka S., Patry L., Nadon M.-A., Mucha B.E., Major P., Shevell M., et al. Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. J.Med. Genet. 2013, 50:740-744.
35. Carson R.P., Fu C., Winzenburger P., Ess K.C. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum. Mol. Genet. 2013, 22:140-152.
36. Casadio A., Martin K.C., Giustetto M., Zhu H., Chen M., Bartsch D., Bailey C.H., Kandel E.R. A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis. Cell 1999, 99:221-237.
37. Chen J., Zheng X.F., Brown E.J., Schreiber S.L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA 1995, 92:4947-4951.
38. Cheng H.-C., Kim S.R., Oo T.F., Kareva T., Yarygina O., Rzhetskaya M., Wang C., During M., Talloczy Z., Tanaka K., et al. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J.Neurosci. 2011, 31:2125-2135.
39. Choi Y.J., Di Nardo A., Kramvis I., Meikle L., Kwiatkowski D.J., Sahin M., He X. Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008, 22:2485-2495.
40. Cloëtta D., Thomanetz V., Baranek C., Lustenberger R.M., Lin S., Oliveri F., Atanasoski S., Rüegg M.A. Inactivation of mTORC1 in the developing brain causes microcephaly and affects gliogenesis. J.Neurosci. 2013, 33:7799-7810.
41. Costa R.M., Yang T., Huynh D.P., Pulst S.M., Viskochil D.H., Silva A.J., Brannan C.I. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat. Genet. 2001, 27:399-405.
42. Cota D., Proulx K., Smith K.A., Kozma S.C., Thomas G., Woods S.C., Seeley R.J. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
43. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N.Engl. J. Med. 2006, 355:1345-1356.
44. Crino P.B., Aronica E., Baltuch G., Nathanson K.L. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 2010, 74:1716-1723.
45. Cunningham J.T., Rodgers J.T., Arlow D.H., Vazquez F., Mootha V.K., Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450:736-740.
46. Dabora S.L., Jozwiak S., Franz D.N., Roberts P.S., Nieto A., Chung J., Choy Y.S., Reeve M.P., Thiele E., Egelhoff J.C., et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 2001, 68:64-80.
47. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y.S., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
48. Dasgupta B., Gutmann D.H. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation invitro and invivo. J.Neurosci. 2005, 25:5584-5594.
49. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005, 65:2755-2760.
50. Davies D.M., de Vries P.J., Johnson S.R., McCartney D.L., Cox J.A., Serra A.L., Watson P.C., Howe C.J., Doyle T., Pointon K., et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 2011, 17:4071-4081.
51. Diggs-Andrews K.A., Gutmann D.H. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci. 2013, 36:237-247.
52. Di Nardo A., Wertz M.H., Kwiatkowski E., Tsai P.T., Leech J.D., Greene-Colozzi E., Goto J., Dilsiz P., Talos D.M., Clish C.B., et al. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Hum. Mol. Genet. 2014, 23:3865-3874.
53. Dibbens L.M., de Vries B., Donatello S., Heron S.E., Hodgson B.L., Chintawar S., Crompton D.E., Hughes J.N., Bellows S.T., Klein K.M., et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat. Genet. 2013, 45:546-551.
54. Dibble C.C., Manning B.D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 2013, 15:555-564.
55. Dibble C.C., Elis W., Menon S., Qin W., Klekota J., Asara J.M., Finan P.M., Kwiatkowski D.J., Murphy L.O., Manning B.D. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol. Cell 2012, 47:535-546.
56. Dixon-Salazar T.J., Fourgeaud L., Tyler C.M., Poole J.R., Park J.J., Boulanger L.M. MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling. J.Neurosci. 2014, 34:11844-11856.
57. Efeyan A., Zoncu R., Chang S., Gumper I., Snitkin H., Wolfson R.L., Kirak O., Sabatini D.D., Sabatini D.M. Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. Nature 2013, 493:679-683.
58. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., Ramesh V., Silva A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14:843-848.
59. Ehninger D., Sano Y., de Vries P.J., Dies K., Franz D., Geschwind D.H., Kaur M., Lee Y.S., Li W., Lowe J.K., et al. Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Mol. Psychiatry 2012, 17:62-70.
60. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
61. Endersby R., Baker S.J. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008, 27:5416-5430.
62. Endo M., Yamamoto H., Setsu N., Kohashi K., Takahashi Y., Ishii T., Iida K., Matsumoto Y., Hakozaki M., Aoki M., et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin. Cancer Res. 2013, 19:450-461.
63. Ertan G., Arulrajah S., Tekes A., Jordan L., Huisman T.A.G.M. Cerebellar abnormality in children and young adults with tuberous sclerosis complex: MR and diffusion weighted imaging findings. J.Neuroradiol. 2010, 37:231-238.
64. Fenton T.R., Gout I.T. Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 2011, 43:47-59.
65. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., Dinopoulos A., Thomas G., Crone K.R. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 2006, 59:490-498.
66. Gkogkas C.G., Khoutorsky A., Ran I., Rampakakis E., Nevarko T., Weatherill D.B., Vasuta C., Yee S., Truitt M., Dallaire P., et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 2013, 493:371-377.
67. Goorden S.M., van Woerden G.M., van der Weerd L., Cheadle J.P., Elgersma Y. Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann. Neurol. 2007, 62:648-655.
68. Goto J., Talos D.M., Klein P., Qin W., Chekaluk Y.I., Anderl S., Malinowska I.A., Di Nardo A., Bronson R.T., Chan J.A., et al. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc. Natl. Acad. Sci. USA 2011, 108:E1070-E1079.
69. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J.Neurochem. 2005, 93:105-117.
70. Guo D., Zeng L., Brody D.L., Wong M. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS ONE 2013, 8:e64078.
71. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
72. Haemel A.K., O'Brian A.L., Teng J.M. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch. Dermatol. 2010, 146:715-718.
73. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
74. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
75. Hentges K.E., Sirry B., Gingeras A.-C., Sarbassov D., Sonenberg N., Sabatini D., Peterson A.S. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc. Natl. Acad. Sci. USA 2001, 98:13796-13801.
76. Hobert J.A., Embacher R., Mester J.L., Frazier T.W., Eng C. Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. Eur. J. Hum. Genet. 2014, 22:273-276.
77. Hoeffer C.A., Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010, 33:67-75.
78. Hoeffer C.A., Tang W., Wong H., Santillan A., Patterson R.J., Martinez L.A., Tejada-Simon M.V., Paylor R., Hamilton S.L., Klann E. Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 2008, 60:832-845.
79. Hou L., Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J.Neurosci. 2004, 24:6352-6361.
80. Huang J., Dibble C.C., Matsuzaki M., Manning B.D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 2008, 28:4104-4115.
81. Huang X., Zhang H., Yang J., Wu J., McMahon J., Lin Y., Cao Z., Gruenthal M., Huang Y. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 2010, 40:193-199.
82. Huang W., Zhu P.J., Zhang S., Zhou H., Stoica L., Galiano M., Krnjević K., Roman G., Costa-Mattioli M. mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat. Neurosci. 2013, 16:441-448.
83. Huber K.M., Kayser M.S., Bear M.F. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 2000, 288:1254-1257.
84. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 2002, 99:7746-7750.
85. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
86. Hunt A., Stores G. Sleep disorder and epilepsy in children with tuberous sclerosis: a questionnaire-based study. Dev. Med. Child Neurol. 1994, 36:108-115.
87. Husain A.M., Foley C.M., Legido A., Chandler D.A., Miles D.K., Grover W.D. Tuberous sclerosis complex and epilepsy: prognostic significance of electroencephalography and magnetic resonance imaging. J.Child Neurol. 2000, 15:81-83.
88. Inoki K., Li Y., Xu T., Guan K.-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17:1829-1834.
89. Inoki K., Kim J., Guan K.-L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 2012, 52:381-400.
90. Jacinto E., Loewith R., Schmidt A., Lin S., Rüegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6:1122-1128.
91. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
92. Jansen F.E., Vincken K.L., Algra A., Anbeek P., Braams O., Nellist M., Zonnenberg B.A., Jennekens-Schinkel A., van den Ouweland A., Halley D., et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 2008, 70:916-923.
93. Jeste S.S., Sahin M., Bolton P., Ploubidis G.B., Humphrey A. Characterization of autism in young children with tuberous sclerosis complex. J.Child Neurol. 2008, 23:520-525.
94. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 2005, 102:8573-8578.
95. Johannessen C.M., Johnson B.W., Williams S.M., Chan A.W., Reczek E.E., Lynch R.C., Rioth M.J., McClatchey A., Ryeom S., Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 2008, 18:56-62.
96. Johnson S.C., Rabinovitch P.S., Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
97. Johnson S.C., Yanos M.E., Kayser E.-B., Quintana A., Sangesland M., Castanza A., Uhde L., Hui J., Wall V.Z., Gagnidze A., et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 2013, 342:1524-1528.
98. Jung H., Gkogkas C.G., Sonenberg N., Holt C.E. Remote control of gene function by local translation. Cell 2014, 157:26-40.
99. Kapahi P., Zid B. TOR pathway: linking nutrient sensing to life span. Sci. SAGE KE 2004, 2004:PE34.
100. Kassai H., Sugaya Y., Noda S., Nakao K., Maeda T., Kano M., Aiba A. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases. Cell Reports 2014, 7:1626-1639.
101. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
102. Kim J.Y., Duan X., Liu C.Y., Jang M.-H., Guo J.U., Pow-anpongkul N., Kang E., Song H., Ming G.L. DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 2009, 63:761-773.
103. Klein S., Sharifi-Hannauer P., Martinez-Agosto J.A. Macrocephaly as a clinical indicator of genetic subtypes in autism. Autism Res. 2013, 6:51-56.
104. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
105. Komatsu M., Wang Q.J., Holstein G.R., Friedrich V.L., Iwata J., Kominami E., Chait B.T., Tanaka K., Yue Z. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc. Natl. Acad. Sci. USA 2007, 104:14489-14494.
106. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., Wilson K.A., Byars A., Sahmoud T., Franz D.N. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N.Engl. J. Med. 2010, 363:1801-1811.
107. Krueger D.A., Wilfong A.A., Holland-Bouley K., Anderson A.E., Agricola K., Tudor C., Mays M., Lopez C.M., Kim M.O., Franz D.N. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann. Neurol. 2013, 74:679-687.
108. Kwon C.-H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W., Li Y., Baker S.J., Parada L.F. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388.
109. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
110. Lebrun-Julien F., Bachmann L., Norrmén C., Trötzmüller M., Köfeler H., Rüegg M.A., Hall M.N., Suter U. Balanced mTORC1 activity in oligodendrocytes is required for accurate CNS myelination. J.Neurosci. 2014, 34:8432-8448.
111. Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T., Heiberg A., Scott E., Bafna V., Hill K.J., Collazo A., et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat. Genet. 2012, 44:941-945.
112. Lenz G., Avruch J. Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. J.Biol. Chem. 2005, 280:38121-38124.
113. Lewis W.W., Sahin M., Scherrer B., Peters J.M., Suarez R.O., Vogel-Farley V.K., Jeste S.S., Gregas M.C., Prabhu S.P., Nelson C.A., Warfield S.K. Impaired language pathways in tuberous sclerosis complex patients with autism spectrum disorders. Cereb. Cortex 2013, 23:1526-1532.
114. Li Y., Inoki K., Guan K.-L. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol. 2004, 24:7965-7975.
115. Li X., Alafuzoff I., Soininen H., Winblad B., Pei J.-J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005, 272:4211-4220.
116. Li N., Lee B., Liu R.-J., Banasr M., Dwyer J.M., Iwata M., Li X.-Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
117. Li N., Liu R.-J., Dwyer J.M., Banasr M., Lee B., Son H., Li X.-Y., Aghajanian G., Duman R.S. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69:754-761.
118. Liu L., Li F., Cardelli J.A., Martin K.A., Blenis J., Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 2006, 25:7029-7040.
119. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 2002, 10:457-468.
120. Lu Y., Belin S., He Z. Signaling regulations of neuronal regenerative ability. Curr. Opin. Neurobiol. 2014, 27:135-142.
121. Lüscher C., Huber K.M. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 2010, 65:445-459.
122. Lynch N.E., Lynch S.A., McMenamin J., Webb D. Bannayan-Riley-Ruvalcaba syndrome: a cause of extreme macrocephaly and neurodevelopmental delay. Arch. Dis. Child. 2009, 94:553-554.
123. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
124. McCormack F.X., Inoue Y., Moss J., Singer L.G., Strange C., Nakata K., Barker A.F., Chapman J.T., Brantly M.L., Stocks J.M., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N.Engl. J. Med. 2011, 364:1595-1606. National Institutes of Health Rare Lung Diseases Consortium, MILES Trial GroupMILES Trial Group.
125. Meikle L., Talos D.M., Onda H., Pollizzi K., Rotenberg A., Sahin M., Jensen F.E., Kwiatkowski D.J. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J.Neurosci. 2007, 27:5546-5558.
126. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., Kwiatkowski D.J. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J.Neurosci. 2008, 28:5422-5432.
127. Menon S., Dibble C.C., Talbott G., Hoxhaj G., Valvezan A.J., Takahashi H., Cantley L.C., Manning B.D. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 2014, 156:771-785.
128. Miyata H., Chiang A.C.Y., Vinters H.V. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann. Neurol. 2004, 56:510-519.
129. Mohamed A.R., Bailey C.A., Freeman J.L., Maixner W., Jackson G.D., Harvey A.S. Intrinsic epileptogenicity of cortical tubers revealed by intracranial EEG monitoring. Neurology 2012, 79:2249-2257.
130. Mori H., Inoki K., Münzberg H., Opland D., Faouzi M., Villanueva E.C., Ikenoue T., Kwiatkowski D., MacDougald O.A., Myers M.G., Guan K.L. Critical role for hypothalamic mTOR activity in energy balance. Cell Metab. 2009, 9:362-374.
131. Nie D., Di Nardo A., Han J.M., Baharanyi H., Kramvis I., Huynh T., Dabora S., Codeluppi S., Pandolfi P.P., Pasquale E.B., Sahin M. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat. Neurosci. 2010, 13:163-172.
132. Nixon R.A. The role of autophagy in neurodegenerative disease. Nat. Med. 2013, 19:983-997.
133. Normand E.A., Crandall S.R., Thorn C.A., Murphy E.M., Voelcker B., Browning C., Machan J.T., Moore C.I., Connors B.W., Zervas M. Temporal and mosaic Tsc1 deletion in the developing thalamus disrupts thalamocortical circuitry, neural function, and behavior. Neuron 2013, 78:895-909.
134. O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., Carvill G., Kumar A., Lee C., Ankenman K., et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012, 338:1619-1622.
135. Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., Miyamoto T., Hara K., Takehana K., Avruch J., et al. The proline-rich Akt substrate of 40kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J.Biol. Chem. 2007, 282:20329-20339.
136. Osterweil E.K., Chuang S.-C., Chubykin A.A., Sidorov M., Bianchi R., Wong R.K.S., Bear M.F. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013, 77:243-250.
137. Park K.K., Liu K., Hu Y., Smith P.D., Wang C., Cai B., Xu B., Connolly L., Kramvis I., Sahin M., He Z. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322:963-966.
138. Pearce L.R., Huang X., Boudeau J., Pawłowski R., Wullschleger S., Deak M., Ibrahim A.F.M., Gourlay R., Magnuson M.A., Alessi D.R. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 2007, 405:513-522.
139. Pei J.-J., Hugon J. mTOR-dependent signalling in Alzheimer's disease. J.Cell. Mol. Med. 2008, 12(6B):2525-2532.
140. Peters J.M., Taquet M., Prohl A.K., Scherrer B., van Eeghen A.M., Prabhu S.P., Sahin M., Warfield S.K. Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions. Future Neurol. 2013, 8:583-597.
141. Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E., Guertin D.A., Madden K.L., Carpenter A.E., Finck B.N., Sabatini D.M. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146:408-420.
142. Pilarski R., Burt R., Kohlman W., Pho L., Shannon K.M., Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J.Natl. Cancer Inst. 2013, 105:1607-1616.
143. Poduri A., Evrony G.D., Cai X., Elhosary P.C., Beroukhim R., Lehtinen M.K., Hills L.B., Heinzen E.L., Hill A., Hill R.S., et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012, 74:41-48.
144. Pun R.Y., Rolle I.J., Lasarge C.L., Hosford B.E., Rosen J.M., Uhl J.D., Schmeltzer S.N., Faulkner C., Bronson S.L., Murphy B.L., et al. Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy. Neuron 2012, 75:1022-1034.
145. Qin W., Chan J.A., Vinters H.V., Mathern G.W., Franz D.N., Taillon B.E., Bouffard P., Kwiatkowski D.J. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol. 2010, 20:1096-1105.
146. Quevedo C., Salinas M., Alcázar A. Regulation of cap-dependent translation by insulin-like growth factor-1 in neuronal cells. Biochem. Biophys. Res. Commun. 2002, 291:560-566.
147. Raab-Graham K.F., Haddick P.C.G., Jan Y.N., Jan L.Y. Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 2006, 314:144-148.
148. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
149. Reith R.M., Way S., McKenna J., Haines K., Gambello M.J. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol. Dis. 2011, 43:113-122.
150. Reith R.M., McKenna J., Wu H., Hashmi S.S., Cho S.H., Dash P.K., Gambello M.J. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 2013, 51:93-103.
151. Richter J.D., Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005, 433:477-480.
152. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2006, 103:18757-18762.
153. Rivière J.-B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 2012, 44:934-940. Finding of Rare Disease Genes (FORGE) Canada Consortium.
154. Rodríguez-Escudero I., Oliver M.D., Andrés-Pons A., Molina M., Cid V.J., Pulido R. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum. Mol. Genet. 2011, 20:4132-4142.
155. Roscic A., Baldo B., Crochemore C., Marcellin D., Paganetti P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J.Neurochem. 2011, 119:398-407.
156. Ross C.A., Aylward E.H., Wild E.J., Langbehn D.R., Long J.D., Warner J.H., Scahill R.I., Leavitt B.R., Stout J.C., Paulsen J.S., et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014, 10:204-216.
157. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78:35-43.
158. Sabatini D.M., Barrow R.K., Blackshaw S., Burnett P.E., Lai M.M., Field M.E., Bahr B.A., Kirsch J., Betz H., Snyder S.H. Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling. Science 1999, 284:1161-1164.
159. Sancak O., Nellist M., Goedbloed M., Elfferich P., Wouters C., Maat-Kievit A., Zonnenberg B., Verhoef S., Halley D., van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur. J. Hum. Genet. 2005, 13:731-741.
160. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007, 25:903-915.
161. Santini E., Huynh T.N., MacAskill A.F., Carter A.G., Pierre P., Ruggero D., Kaphzan H., Klann E. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 2013, 493:411-415.
162. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
163. Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
164. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
165. Sato A., Kasai S., Kobayashi T., Takamatsu Y., Hino O., Ikeda K., Mizuguchi M. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat. Commun. 2012, 3:1292.
166. Scheffer I.E., Heron S.E., Regan B.M., Mandelstam S., Crompton D.E., Hodgson B.L., Licchetta L., Provini F., Bisulli F., Vadlamudi L., et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann. Neurol. 2014, 75:782-787.
167. Seibt J., Frank M.G. Translation regulation in sleep: Making experience last. Commun. Integr. Biol. 2012, 5:491-495.
168. Seibt J., Dumoulin M.C., Aton S.J., Coleman T., Watson A., Naidoo N., Frank M.G. Protein synthesis during sleep consolidates cortical plasticity invivo. Curr. Biol. 2012, 22:676-682.
169. Selman C., Tullet J.M.A., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., Claret M., Al-Qassab H., Carmignac D., Ramadani F., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
170. Sharma A., Hoeffer C.A., Takayasu Y., Miyawaki T., McBride S.M., Klann E., Zukin R.S. Dysregulation of mTOR signaling in fragile X syndrome. J.Neurosci. 2010, 30:694-702.
171. Sharp F.R., Bernaudin M. HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci. 2004, 5:437-448.
172. Siuta M.A., Robertson S.D., Kocalis H., Saunders C., Gresch P.J., Khatri V., Shiota C., Kennedy J.P., Lindsley C.W., Daws L.C., et al. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol. 2010, 8:e1000393.
173. Sonenberg N., Hinnebusch A.G. New modes of translational control in development, behavior, and disease. Mol. Cell 2007, 28:721-729.
174. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T., Masliah E. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J.Neurosci. 2009, 29:13578-13588.
175. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e9979.
176. Stan R., McLaughlin M.M., Cafferkey R., Johnson R.K., Rosenberg M., Livi G.P. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J.Biol. Chem. 1994, 269:32027-32030.
177. Sternson S.M. Hypothalamic survival circuits: blueprints for purposive behaviors. Neuron 2013, 77:810-824.
178. Südhof T.C. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008, 455:903-911.
179. Taghibiglou C., Martin H.G.S., Lai T.W., Cho T., Prasad S., Kojic L., Lu J., Liu Y., Lo E., Zhang S., et al. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat. Med. 2009, 15:1399-1406.
180. Takahashi J.S., Hong H.K., Ko C.H., McDearmon E.L. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat. Rev. Genet. 2008, 9:764-775.
181. Takei N., Inamura N., Kawamura M., Namba H., Hara K., Yonezawa K., Nawa H. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J.Neurosci. 2004, 24:9760-9769.
182. Tang S.J., Reis G., Kang H., Gingras A.-C., Sonenberg N., Schuman E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. USA 2002, 99:467-472.
183. Tang G., Gudsnuk K., Kuo S.H., Cotrina M.L., Rosoklija G., Sosunov A., Sonders M.S., Kanter E., Castagna C., Yamamoto A., et al. Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits. Neuron 2014, 83:1131-1143.
184. Tavazoie S.F., Alvarez V.A., Ridenour D.A., Kwiatkowski D.J., Sabatini B.L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 2005, 8:1727-1734.
185. Thomanetz V., Angliker N., Cloëtta D., Lustenberger R.M., Schweighauser M., Oliveri F., Suzuki N., Rüegg M.A. Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology. J.Cell Biol. 2013, 201:293-308.
186. Tillema J.-M., Leach J.L., Krueger D.A., Franz D.N. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology 2012, 78:526-531.
187. Tononi G., Cirelli C. Staying awake puts pressure on brain arousal systems. J.Clin. Invest. 2007, 117:3648-3650.
188. Tsai P.T., Hull C., Chu Y., Greene-Colozzi E., Sadowski A.R., Leech J.M., Steinberg J., Crawley J.N., Regehr W.G., Sahin M. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012, 488:647-651.
189. Tsvetkov A.S., Miller J., Arrasate M., Wong J.S., Pleiss M.A., Finkbeiner S. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc. Natl. Acad. Sci. USA 2010, 107:16982-16987.
190. Uhlmann E.J., Wong M., Baldwin R.L., Bajenaru M.L., Onda H., Kwiatkowski D.J., Yamada K., Gutmann D.H. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 2002, 52:285-296.
191. Urbanska M., Gozdz A., Swiech L.J., Jaworski J. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J.Biol. Chem. 2012, 287:30240-30256.
192. van Slegtenhorst M., Verhoef S., Tempelaars A., Bakker L., Wang Q., Wessels M., Bakker R., Nellist M., Lindhout D., Halley D., van den Ouweland A. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J.Med. Genet. 1999, 36:285-289.
193. Vander Haar E., Lee S.-I., Bandhakavi S., Griffin T.J., Kim D.-H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007, 9:316-323.
194. Varga E.A., Pastore M., Prior T., Herman G.E., McBride K.L. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet. Med. 2009, 11:111-117.
195. Verma P., Chierzi S., Codd A.M., Campbell D.S., Meyer R.L., Holt C.E., Fawcett J.W. Axonal protein synthesis and degradation are necessary for efficient growth cone regeneration. J.Neurosci. 2005, 25:331-342.
196. von der Brelie C., Waltereit R., Zhang L., Beck H., Kirschstein T. Impaired synaptic plasticity in a rat model of tuberous sclerosis. Eur. J. Neurosci. 2006, 23:686-692.
197. Wahl S.E., McLane L.E., Bercury K.K., Macklin W.B., Wood T.L. Mammalian target of rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination. J.Neurosci. 2014, 34:4453-4465.
198. Waltereit R., Japs B., Schneider M., de Vries P.J., Bartsch D. Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats. Behav. Genet. 2011, 41:364-372.
199. Wang C., Yu J.-T., Miao D., Wu Z.-C., Tan M.-S., Tan L. Targeting the mTOR signaling network for Alzheimer's disease therapy. Mol. Neurobiol. 2014, 49:120-135.
200. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J.Biol. Chem. 2003, 278:25009-25013.
201. Woods S.C., Seeley R.J., Cota D. Regulation of food intake through hypothalamic signaling networks involving mTOR. Annu. Rev. Nutr. 2008, 28:295-311.
202. Yang S.B., Tien A.C., Boddupalli G., Xu A.W., Jan Y.N., Jan L.Y. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012, 75:425-436.
203. Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P. mTOR kinase structure, mechanism and regulation. Nature 2013, 497:217-223.
204. Yoon B.C., Zivraj K.H., Holt C.E. Local translation and mRNA trafficking in axon pathfinding. Results Probl. Cell Differ. 2009, 48:269-288.
205. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
206. Zeng L.H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008, 63:444-453.
207. Zeng L.-H., Rensing N.R., Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J.Neurosci. 2009, 29:6964-6972.
208. Zeng L.H., Rensing N.R., Zhang B., Gutmann D.H., Gambello M.J., Wong M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum. Mol. Genet. 2011, 20:445-454.
209. Zhang S., Salemi J., Hou H., Zhu Y., Mori T., Giunta B., Obregon D., Tan J. Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. Biochem. Biophys. Res. Commun. 2010, 398:337-341.
210. Zhou J., Parada L.F. PTEN signaling in autism spectrum disorders. Curr. Opin. Neurobiol. 2012, 22:873-879.
211. Zhou J., Blundell J., Ogawa S., Kwon C.-H., Zhang W., Sinton C., Powell C.M., Parada L.F. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J.Neurosci. 2009, 29:1773-1783.
212. Zhou M., Li W., Huang S., Song J., Kim J.Y., Tian X., Kang E., Sano Y., Liu C., Balaji J., et al. mTOR Inhibition ameliorates cognitive and affective deficits caused by Disc1 knockdown in adult-born dentate granule neurons. Neuron 2013, 77:647-654.
213. Zid B.M., Rogers A.N., Katewa S.D., Vargas M.A., Kolipinski M.C., Lu T.A., Benzer S., Kapahi P. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 2009, 139:149-160.
214. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144:757-768.
215. Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y., Sabatini D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011, 334:678-683.
216. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.